





CZECH REPUBLIC

Recent and planned developments in pharmaceutical policies 2015 Pre-launch activities: horizon scanning and forecasting

Changes in pricing	Changes in reimbursement
 No relevant system changes in 2014 Launch of 3rd wave of price review in 2015 01/01/2015: Decrease of VAT rate on medicines from 15% to 10% (affects retail price automatically) (nutritional supplements for children over 3 years and for adults stay in 15% rate) 	 No relevant system changes in 2014 Ongoing 2nd wave of reimbursement reviews Launch of 3rd wave of complex reimbursement review in 2015 01/01/2015: Decrease of VAT rate on medicines from 15% to 10% (affects reimbursement price automatically) (nutritional supplements for children over 3 years and for adults stay in 15% rate)
Other changes • 01/01/2015: Dispensing fee and clinical examination fee cancelled (currently approx. €1.1).	
Pre-launch pharmaceutical policies: Horizon scanning and forecasts	
We do not currently have any official horizon scanning program established in the Czech Republic. It is not planned regular activity in near future. SUKL has recently conducted an ad hoc horizon scanning exercise upon Ministry of Health request. Its main motivation has been an estimation of budget impact of new medicines entering the market in first half of 2015 (the exercise focused on highly innovative and very expensive medicines that are used in centres of excellence). The exercise has been conducted in August and September 2014 and analysed costs and reimbursements of medicines entering the market for severe illnesses which will be used only in centres of excellence. These centres must have contract with insurance companies to provide this kind of covered care. Results of the exercise have been transferred to the Ministry of Health. No outcomes have been officially published.	
	No relevant system changes in 2014 Launch of 3 rd wave of price review in 2015 O1/01/2015: Decrease of VAT rate on medicines from 15% to 10% (affects retail price automatically) (nutritional supplements for children over 3 years and for adults stay in 15% rate) Other O1/01/2015: Dispensing fee and clinical example. Pre-launch pharmaceutical policy. We do not currently have any official horizon. It is not planned regular activity in near future. SUKL has recently conducted an ad hoc request. Its main motivation has been an estime market in first half of 2015 (the exercise focuse that are used in centres of excellence). The exercise has been conducted in Augental states.